Your browser doesn't support javascript.
loading
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.
Brown, Patrick A; Wieduwilt, Matthew; Logan, Aaron; DeAngelo, Daniel J; Wang, Eunice S; Fathi, Amir; Cassaday, Ryan D; Litzow, Mark; Advani, Anjali; Aoun, Patricia; Bhatnagar, Bhavana; Boyer, Michael W; Bryan, Teresa; Burke, Patrick W; Coccia, Peter F; Coutre, Steven E; Jain, Nitin; Kirby, Suzanne; Liu, Arthur; Massaro, Stephanie; Mattison, Ryan J; Oluwole, Olalekan; Papadantonakis, Nikolaos; Park, Jae; Rubnitz, Jeffrey E; Uy, Geoffrey L; Gregory, Kristina M; Ogba, Ndiya; Shah, Bijal.
Afiliação
  • Brown PA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Wieduwilt M; UC San Diego Moores Cancer Center.
  • Logan A; UCSF Helen Diller Comprehensive Cancer Center.
  • DeAngelo DJ; Dana-Farber/Brigham and Women's Cancer Center.
  • Wang ES; Roswell Park Comprehensive Cancer Center.
  • Fathi A; Massachusetts General Hospital Cancer Center.
  • Cassaday RD; University of Washington/Seattle Cancer Care Alliance.
  • Litzow M; Mayo Clinic Cancer Center.
  • Advani A; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Aoun P; City of Hope National Medical Center.
  • Bhatnagar B; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Boyer MW; Huntsman Cancer Institute at the University of Utah.
  • Bryan T; University of Alabama at Birmingham Comprehensive Cancer Center.
  • Burke PW; University of Michigan Rogel Cancer Center.
  • Coccia PF; Fred & Pamela Buffett Cancer Center.
  • Coutre SE; Stanford Cancer Institute.
  • Jain N; The University of Texas MD Anderson Cancer Center.
  • Kirby S; Duke Cancer Institute.
  • Liu A; University of Colorado Cancer Center.
  • Massaro S; Yale Cancer Center/Smilow Cancer Hospital.
  • Mattison RJ; University of Wisconsin Carbone Cancer Center.
  • Oluwole O; Vanderbilt-Ingram Cancer Center.
  • Papadantonakis N; University of Alabama at Birmingham Comprehensive Cancer Center.
  • Park J; Memorial Sloan Kettering Cancer Center.
  • Rubnitz JE; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Uy GL; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Gregory KM; National Comprehensive Cancer Network; and.
  • Ogba N; National Comprehensive Cancer Network; and.
  • Shah B; Moffitt Cancer Center.
J Natl Compr Canc Netw ; 17(5): 414-423, 2019 05 01.
Article em En | MEDLINE | ID: mdl-31085755
ABSTRACT
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Guias de Prática Clínica como Assunto / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Etiology_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article